Načítá se...
Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts()
Immunogenicity remains the ‘Achilles’ heel’ of protein-based therapeutics. Anti-drug antibodies produced in response to protein therapeutics can severely limit both the safety and efficacy of this expanding class of agent. Here we report that monotherapy of mice with tofacitinib (the Janus kinase in...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4106678/ https://ncbi.nlm.nih.gov/pubmed/24890727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1400063 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|